Earnings Releases·Nov 6, 2026, 5:18 PM ET

Quoin Pharmaceuticals — Third Quarter 2026 Earnings Summary

Reported a net loss of $4.9 million for Q3 2026 (up from $3.9 million in 2025) and $15.2 million for the nine months ended September 30, 2026 (up from $11.5 million in 2025), with cash and marketable securities rising to $33.2 million as of September 30, 2026.
Completed a private placement financing on August 28, 2026, providing an initial $30.8 million and up to $19.2 million in potential warrant proceeds, increasing total shareholders' equity to $28.7 million and ordinary shares outstanding to 168.1 million.
Announced positive interim data for QRX003 in Netherton Syndrome (66.7% of participants achieved primary endpoint) and secured FDA IND clearance, Rare Pediatric Disease, and Fast Track designations for Peeling Skin Syndrome.
Outlined a clinical roadmap to complete Netherton Syndrome recruitment by end of 2026 with topline data expected in Q2 2027, initiate Peeling Skin Syndrome studies before year-end 2026, and advance QRX009 toward clinical testing in early 2027.
Management projects current cash resources will fund operations through 2028, positioning the company to potentially deliver the first approved treatment for Netherton Syndrome.